FindTrial
Sign In

Study on the response of two doses of ixizumab in the treatment of moderate to severe plaque psoriasis

Study on the response of two doses of ixizumab in the treatment of moderate to severe plaque psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052880
Enrollment
Unknown
Registered
2021-11-06
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Experimental group:Ixizumab 80 mg subcutaneously (week 0 and 2)

Sponsors

The University of Hong Kong-Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed patients with moderate and severe psoriasis; 2. Aged >= 18 years, no gender limit; 3. Pass the screening and meet the standards for the use of ixizumab; 4. Volunteer to participate in this study, able to adhere to follow-up, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have a history of latent tuberculosis, hepatitis B, or tumors, and those who have failed the screening of biological agents; 2. Patients who are receiving or have previously received biological treatment.

Design outcomes

Primary

MeasureTime frame
Severity of illness;PASI (Psoriasis area and severity index);DLQI (Dermatology Life Quality Index);—

Countries

China

Contacts

Public ContactLiu Xiaoming

The University of Hong Kong-Shenzhen Hospital

liuxm@hku-szh.org+86 18307556805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026